is fda stopping semaglutide Compound versions of GLP-1 drugs for weight loss halted by September 15, 2025: Telehealth company

European Multicentre Orlistat Study Group

Understanding Semaglutide and GLP-1 Medications Semaglutide belongs to a class of medications known as GLP-1 receptor agonists

In some cases, people may experience severe adverse health conditions, including allergic reactions, vision changes, and pancreatitis

Average weight loss ranges from 1015% of body weight over 12 weeks with consistent semaglutide use, though individual timelines vary widely based on starting weight, genetics, and adherence

Others roughly 10% to 15% of patients lose close to no weight at all, even at the maximum dose

At $119 per month flat-rate, this is one of the most affordable compounded semaglutide options available